Long-acting risperidone improves negative symptoms in stable psychotic patients

被引：0
|
作者：
Curtis, V. A.
Katsafouros, K.
Moeller, H. J.
Medori, R.
Sacchetti, E.
机构：
[1] Maudsley Hosp & Inst Psychiat, Inst Psychiat, London SE5 8AZ, England
[2] Dromokait State Hosp, Psychotherapeut Ctr, Tarsi Psychiat Clin, Athens, Greece
[3] Univ Munich, Dept Psychiat, D-8000 Munich, Germany
[4] Med Affairs EMEA, Beerse, Belgium
[5] Univ Brescia, Sch Med, Univ Psychiat Unit, Brescia, Italy
[6] Brescia Spedali Civili, Dept Mental Hlth, Brescia, Italy
来源：
EUROPEAN PSYCHIATRY | 2007年 / 22卷
关键词：
D O I：
10.1016/j.eurpsy.2007.01.487
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：S151 / S151
页数：1
相关论文
共 50 条
  • [31] COST OF LONG-ACTING RISPERIDONE INJECTION VERSUS LONG-ACTING PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA
    Omelyanovsky, V
    Avxentyeva, M.
    Ivakhnenko, O.
    Khailov, P.
    Tsfasman, F. M.
    Krysanov, I
    Zorin, N.
    VALUE IN HEALTH, 2012, 15 (07) : A338 - A338
  • [32] Effect of long-acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients
    Ibach, B.
    Bossie, C.
    Turkoz, I.
    Haskins, T.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 157 - 157
  • [33] Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial
    Lasser, RA
    Bossie, CA
    Gharabawi, GM
    Baldessarini, RJ
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2005, 8 (03): : 427 - 438
  • [34] Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
    Rosa, Fernanda
    Schreiner, Andreas
    Thomas, Pierre
    Sherif, Tarek
    CLINICAL DRUG INVESTIGATION, 2012, 32 (04) : 267 - 279
  • [35] Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
    Fernanda Rosa
    Andreas Schreiner
    Pierre Thomas
    Tarek Sherif
    Clinical Drug Investigation, 2012, 32 : 267 - 279
  • [36] Variations in prolactin levels and related symptoms in schizophrenic patients treated with long-acting injectable risperidone
    Kalkavoura, C.
    Theodorou, A.
    Theodoropoulou, P.
    Tzebelikos, E.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S252 - S252
  • [37] Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone
    Bayle, Franck Jean
    Tessier, Arnaud
    Bouju, Sophie
    Misdrahi, David
    PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 1333 - 1341
  • [38] Long-acting risperidone:: Focus on safety
    Mueller, Hans-Juergen
    CLINICAL THERAPEUTICS, 2006, 28 (05) : 633 - 651
  • [39] Improved symptom control with risperidone long-acting injectable in psychotic patients previously treated with an oral atypical antipsychotic
    Glue, P
    Chrzanowski, W
    Kissling, W
    Buccomino, D
    Medori, R
    Parellada, E
    EUROPEAN PSYCHIATRY, 2005, 20 : S79 - S79
  • [40] Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients
    Girardi, P.
    Serafini, G.
    Pompili, M.
    Innamorati, M.
    Tatarelli, R.
    Baldessarini, R. J.
    PHARMACOPSYCHIATRY, 2010, 43 (02) : 66 - 72
12345